Text Size

Endophthalmitis Cultures (PROSPER)

This study is currently recruiting participants.
Verified July 2011 by Vanderbilt University
Sponsor:
Information provided by (Responsible Party):
Stephen J. Kim, MD, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT01496794
First received: December 19, 2011
Last updated: NA
Last verified: July 2011
History: No changes posted
  Purpose

The intent of this surveillance study will be to obtain written permission from patients with bacterial endophthalmitis in order to compare sterilization rates of their cultured bacterial isolates to standard therapy (vancomycin and ceftazidime) versus combination therapy with vancomycin, ceftazidime, and moxifloxacin.

Research hypothesis:

  1. Cultured bacterial isolates will demonstrate faster in vitro sterilization rates with combination treatment (vancomycin, ceftazidime, and moxifloxacin) compared to "standard therapy" with vancomycin and ceftazidime.
  2. Longitudinal analysis of resistance patterns of cultured isolates will show increasing rates of multi-antibiotic resistance.

Condition
Endophthalmitis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study

Resource links provided by NLM:

MedlinePlus related topics: Antibiotics
U.S. FDA Resources

Further study details as provided by Vanderbilt University:

Estimated Enrollment: 10
Study Start Date: October 2011
Estimated Study Completion Date: August 2013
Groups/Cohorts
Endophthalmitis cultures

Detailed Description:

Adult patients over 18 years of age presenting with endophthalmitis and able to sign consent.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Vanderbilt Eye Institute

Criteria

Inclusion Criteria:

  • all adult patients age 18 or greater presenting with bacterial endophthalmitis to the Vanderbilt Eye Institute and who grow positive cultures

Exclusion Criteria:

  • Patients < 18 years of age or those patients without positive cultures
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01496794

Contacts
Contact: Stephen J Kim, MD 615-936-2020 stephen.j.kim@vanderbilt.edu

Locations
United States, Tennessee
Vanderbilt Eye Institute Recruiting
Nashville, Tennessee, United States, 37232
Contact: Stephen J Kim, MD     615-936-2020     stephen.j.kim@vanderbilt.edu    
Principal Investigator: Stephen J Kim, MD            
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Stephen J Kim, MD Vanderbilt University
  More Information

No publications provided

Responsible Party: Stephen J. Kim, MD, Assistant Professor of Ophthalmology, Vanderbilt University
ClinicalTrials.gov Identifier: NCT01496794     History of Changes
Other Study ID Numbers: 100487
Study First Received: December 19, 2011
Last Updated: December 19, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Endophthalmitis
Eye Infections
Infection
Eye Diseases

ClinicalTrials.gov processed this record on May 23, 2013